Agilent and Transcriptic have agreed to a collaboration through which Transcriptic is adding a number of Agilent genomics products for mutagenesis and cloning to its robotic cloud laboratory. The first Agilent technology to be included in Transcriptic's protocol library and laboratory is Agilent QuikChange Lightning for site-directed mutagenesis.
Transcriptic’s cloud-based service allows users to design their molecular biology experiments through a web-based portal, have them run on Transcriptic’s fully automated cell and molecular biology laboratory, and then have the results available for viewing anywhere in the world. The companies claim that providing Agilent bioreagents in a robotic laboratory setting will offer optimized workflows for customers.
“Agilent QuikChange site-directed mutagenesis kits have an unsurpassed reputation for being reliable and easy to use,” said Yvonne Linney, COO, Transcriptic. “By bringing these products to Transcriptic, we will make it extremely easy for customers to scale up their research, using many mutants to produce very large datasets for exploring protein function.”
In November, Transcriptic raised $13.4 million in a Series A-1 investment round with new and existing investors. The funds will be used to extend the firm’s platform capabilities.